Thinking About Going from Tirzepatide to Retatrutide?

You've been reading about retatrutide and wondering whether your current treatment is already the best it gets

That is a reasonable place to be. You are on Mounjaro, progress has maybe slowed, and a headline about a new Eli Lilly drug promising even greater losses has landed in your feed. The first practical check you can do right now (in under a minute) is to look up retatrutide on the MHRA's Drug Safety Update index: you will find no approved product entry, because the medicine has not been authorised here. That single search tells you the current position without wading through trial press releases.

Retatrutide works on three receptor pathways: GIP, GLP-1 and glucagon. Tirzepatide, the active ingredient in Mounjaro, activates two of those, GIP and GLP-1. The addition of glucagon-receptor activity in retatrutide is designed to increase energy expenditure alongside appetite suppression, and phase 2 data published in The Lancet showed average weight reductions of around 24% at the highest dose over 48 weeks. Those numbers drew significant attention. They do not, on their own, translate into a licensed product you can switch to.

Phase 3 is a longer process. It needs larger populations, longer follow-up and safety data across diverse groups before any regulator can evaluate a submission. Eli Lilly's phase 3 retatrutide programme is under way, but an MHRA decision is at least several years away under realistic timelines. Describing a specific launch date would be speculation, and we won't do that.

What actually happens when you want to move between weight-loss medicines

Even when two licensed medicines exist (say, switching between Wegovy and Mounjaro) the process is a clinical one, not a patient-led one. A prescriber reviews your current dose, your progress, any side effects, and whether the new agent is appropriate for your weight-related health picture. They document a clinical rationale. They consider wash-out periods and titration schedules for the new medicine.

Going from tirzepatide to retatrutide adds a further layer: the destination medicine is not licensed. In the UK, a prescriber can issue an unlicensed ('off-label' is a related but distinct concept) prescription only in specific circumstances, with informed consent and documented clinical justification. Practically, there is no regulated supply chain for retatrutide in the UK, no MHRA-approved patient information leaflet and no GPhC-registered pharmacy able to dispense it lawfully. Patients who find sellers offering it online should treat that as a serious red flag, the MHRA has warned repeatedly about unlicensed medicines sold via unregulated channels. You can report suspect sellers at yellowcard.mhra.gov.uk.

The comparison between the two agents in trial conditions is covered in more depth on our page about how retatrutide differs from tirzepatide, useful background if you want the mechanistic detail without the commercial noise.

Where tirzepatide actually sits right now, and what 'plateau' often means in practice

A weight-loss plateau on Mounjaro is not the same as the medicine failing. NICE's appraisal of tirzepatide (TA1026) notes that the medicine is reviewed if less than 5% body weight is lost after six months at the highest tolerated dose, but most people reach meaningful loss well before that threshold becomes relevant. Plateaus that appear during titration often reflect the body adjusting to a new dose rather than a ceiling effect.

Dose optimisation, dietary protein intake, activity level and whether the current pen is being stored correctly all affect results before any switch makes clinical sense. For context on the cost and supply picture around tirzepatide, Eli Lilly's UK pricing changes from September 2025 are worth understanding if you are comparing private providers.

If your prescriber has reviewed your progress and agrees that your treatment plan needs revisiting, that is exactly the conversation to have at your next clinical review. Our prescribers are available to discuss your weight-loss treatment options based on what is actually licensed and available.

The practical question to bring to your next review

Rather than asking 'can I switch to retatrutide', the more useful clinical question is 'am I on the right dose of my current treatment, and is there anything that should change?' That is answerable now. The retatrutide question may become answerable in future, depending on MHRA review and licensing timelines, but no reputable UK pharmacy can help with it today.

If you want to understand the broader landscape (including what a transition between these two agents might look like once licensing exists) our page on moving from tirzepatide to retatrutide covers that in detail. And if you have specific questions about your current Mounjaro treatment, our clinical team profiles are on the about us page.

For patients curious about tirzepatide's full clinical profile before any switching decision, the tirzepatide treatment overview is a good starting point. Any decision to change treatment (to another licensed medicine or to anything else) begins with a prescriber. That is not a bureaucratic hurdle; it is the mechanism that keeps the process safe. Speak to our prescribers if you would like to start that conversation.